Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $3.2 million.

  • Fennec Pharmaceuticals' Net Cash Flow rose 21858.08% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year decrease of 16580.35%. This contributed to the annual value of $13.4 million for FY2024, which is 22722.51% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Net Cash Flow stood at $3.2 million, which was up 21858.08% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Net Cash Flow ranged from a high of $37.9 million in Q1 2024 and a low of -$13.7 million during Q4 2024
  • Moreover, its 5-year median value for Net Cash Flow was -$3.4 million (2022), whereas its average is -$284444.4.
  • Within the past 5 years, the most significant YoY rise in Fennec Pharmaceuticals' Net Cash Flow was 80421.62% (2024), while the steepest drop was 167310.34% (2024).
  • Over the past 5 years, Fennec Pharmaceuticals' Net Cash Flow (Quarter) stood at -$3.0 million in 2021, then tumbled by 102.1% to -$6.0 million in 2022, then surged by 114.55% to $870000.0 in 2023, then plummeted by 1673.1% to -$13.7 million in 2024, then soared by 123.69% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, -$4.0 million for Q2 2025, and -$4.0 million during Q1 2025.